Molbio Diagnostics IPO: A High-Risk Opportunity for Investors

Molbio Diagnostics, a key player in the molecular diagnostics sector, is set to raise ₹200 crore through a fresh issue of shares aimed at enhancing its capital expenditures. The company also plans to reduce its promoter stake by raising ₹740 crore via an offer for sale, which will see the promoter group's ownership fall from 46.6% to 43% post-IPO.

Global Reach and Revenue Growth

With six manufacturing sites and operations in over 90 countries, Molbio Diagnostics has established itself as a significant contributor to global health programs. The company caters to a diverse clientele, including government health programs, diagnostic labs, hospitals, and international healthcare organizations. A substantial portion of its revenue, over 80%, is derived from government and international aid agencies.

The company's flagship product, the 'Truenat' platform, offers portable diagnostic solutions capable of delivering accurate results within an hour, specifically designed for resource-limited settings. This platform covers over 30 diseases through 43 diagnostic assays. Notably, 74% of the company's revenue comes from test kits, with a significant 70% of this amount generated from tuberculosis diagnostic kits.

Financial Performance

Molbio Diagnostics has reported robust financial growth, with revenue from operations rising by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore. The company's EBITDA also showed impressive growth, increasing by 33.2% to ₹328.2 crore, with an EBITDA margin improvement to 22.6% in FY26 from 22% in FY24.

For the fiscal year 2026, the company saw a year-on-year revenue increase of 41.7%, while EBITDA rose by 27.9%, and net profit grew by 18.4%.

Investment Considerations

Post-IPO, Molbio Diagnostics demands a price-earnings (P/E) multiple of up to 57. Although the company lacks a directly comparable listed peer in India, other healthcare diagnostics and medical device firms such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade at P/E multiples between 54 and 81.

Molbio Diagnostics' IPO presents a potentially lucrative opportunity for high-risk investors, given its substantial revenue growth and global presence. However, the company's customer concentration and reliance on a few key clients remain factors to consider.